Washington, D.C. — A surprising shift in childhood vaccine recommendations is raising concerns among doctors, even as new data confirms the dramatic impact of recently approved respiratory syncytial virus (RSV) shots in reducing hospitalizations. The Trump administration, led by health secretary Robert F. Kennedy Jr., announced restrictions last week on roughly one-third of routine childhood vaccines, narrowing RSV shot eligibility to high-risk infants only.
RSV Shot Rollback: Why Experts Are Worried
Despite evidence showing significant reductions in severe illness, access to crucial RSV protection is shrinking.
- The RSV vaccine is 70% effective at preventing hospitalization when given during pregnancy, and 81% effective when given directly to newborns.
- The vast majority (81%) of babies hospitalized with RSV have no underlying health conditions, making universal vaccination crucial.
- Restricting access could lead to hospitals running out of beds during peak RSV season, reversing recent gains.
- The decision to limit access appears to be politically motivated, with experts expressing surprise and concern.
What’s the most effective way to protect babies from RSV? According to recent studies, the newborn shot is more effective at preventing child hospitalization compared to the pregnancy shot, though both worked well. RSV vaccination during pregnancy is 70% effective at preventing hospitalization, while the newborn shot boasts an 81% effectiveness rate.
The United Kingdom, Australia, and Denmark recommend the RSV shot only for high-risk newborns, but their approach is coupled with universal healthcare systems—ensuring regular doctor visits and vaccine access. In the U.S., where healthcare is more fragmented, only about one-third of pregnant people currently receive the RSV shot, according to the Centers for Disease Control and Prevention (CDC).
As RSV infections and hospitalizations begin to climb this respiratory season, doctors are witnessing a clear benefit from the shots. “It’s easy to see in real life. We can really tell that hospitalizations are down,” said Richard Rupp, professor in pediatrics at the University of Texas Medical Branch and the interim director of the Sealy Institute for Vaccine Sciences, who participated in trials of the RSV shots. “It’s made a big difference.”
Four studies published in JAMA corroborate these observations, echoing previous data demonstrating a significant decline in hospitalizations linked to the shots. Doctors recall a time when hospitals were overwhelmed with infants struggling to breathe during RSV season, sometimes lacking enough beds to accommodate them all. They fear restricting the shots will lead to a resurgence of these scenes.
Kevin Ault, an obstetrician-gynecologist and former member of the Advisory Committee on Immunization Practices (ACIP) RSV working group, emphasized that 81% of babies hospitalized with RSV have no underlying conditions. Limiting the shot to children with existing health issues will “miss a large majority of the potential cases,” he warned. “That’s very concerning, and that’s why a universal recommendation was made.”
Rupp described RSV as “a horrible disease,” explaining how it can rapidly escalate from a mild cold to a life-threatening struggle for breath. “At first, it might seem like a child has a little cold, but then things can change – and quickly. In an hour or two, it can turn the other way,” with the child “fighting for every breath … The fear is always that they’ll just stop.”
The infant RSV shots aren’t traditional vaccines; they are monoclonal antibodies—lab-created antibodies that provide protection for several months until their effectiveness wanes. Experts were taken aback by the Trump administration’s decision to target these shots.
“I was caught, I’ve got to say, flat-footed on the whole RSV thing,” Rupp admitted. “I was surprised, because this sort of seems like an attack on monoclonal antibodies.” He pointed out that even individuals skeptical of COVID-19 vaccines readily sought monoclonal antibody treatments for the virus. Earlier versions of these antibodies have been safely used in children for decades.
“I could not even imagine that we would be at this spot with anybody even doubting that it was something that should be available for all the kids,” Rupp said.
Ault characterized the decision as “made by political appointees without a scientific basis.” Tracy Beth Høeg, recently appointed as the top drugs regulator at the Food and Drug Administration (FDA), claimed that babies in the clinical trials experienced a higher death rate—though she acknowledged this difference wasn’t statistically significant. The FDA subsequently launched an investigation into the shots’ safety.
Ault clarified that there were three deaths in the trials, “but they were months and months and months after the vaccine, and they were due to things like dehydration.” Millions of infants have since received the shots without any reported safety concerns.
The limitations on shot availability will likely worsen access, even for high-risk babies, Ault warned. “If you start having [more] fragmentation of the system, you’re going to see hospitals and offices not stocking it. So even if it’s covered on paper, it might not be available.”
This policy shift has left hospitals, pediatricians, and state and local governments scrambling to establish best practices during RSV season, potentially leading to confusion about who should administer the shots. A pediatrician might assume a baby received the shot at the hospital, while hospital staff might expect parents to consult their pediatrician.
“There’s a quick breakdown in coordination and coverage that way,” Ault said.
More than half of children in the U.S. receive vaccinations through the federal Vaccines for Children program. While officials state the restricted shots will remain available through Medicaid and other federal programs, experts fear this could change at any time.
“Everybody’s big concern is whether or not it will be covered by insurance and by the Vaccines for Children program,” Rupp said. “Those are the people who really will not be able to afford to have this for their children.”
Adding to the complexity, the definition of “high risk” remains unclear. Ault argued that, given the high hospitalization rate among infants with no preexisting conditions, all babies should be eligible. “All babies in the first few months of life are at high risk for RSV,” he said.
